Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 7/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 5/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.37 |
| ▸ | CSF1R | P07333 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638656 | 1.00 | AXL (0.47) | AXLKDRINSRCDK4CDK6 | |
| SCHEMBL467708 | 0.76 | AXL (0.73) | AXLKDRINSRFLT3BACE1 | |
| SCHEMBL30090795 | 0.76 | AXL (0.73) | AXLKDRINSRFLT3BACE1 | |
| SCHEMBL30121704 | 0.76 | AXL (0.48) | AXLKDRINSRCDK4CDK6 | |
| SCHEMBL30090858 | 0.74 | AXL (0.54) | AXLKDRINSRCDK4CDK6 | |
| SCHEMBL1640213 | 0.74 | AXL (0.54) | AXLKDRINSRCDK4CDK6 | |
| SCHEMBL1638201 | 0.73 | FLT3 (0.58) | AXLKDRINSRCDK4JAK2 | |
| SCHEMBL30258892 | 0.73 | FLT3 (0.58) | AXLKDRINSRCDK4JAK2 | |
| SCHEMBL1331409 | 0.72 | AXL (0.50) | AXLKDRINSRCDK4CDK6 | |
| SCHEMBL30090873 | 0.72 | AXL (0.69) | AXLKDRINSRFLT3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | AXL 1/4885KDR 735/4885INSR 1338/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | AXL 2/4885KDR 166/4885INSR 1410/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | AXL 3/4885KDR 834/4885INSR 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.